trending Market Intelligence /marketintelligence/en/news-insights/trending/wt0vjpi-dkyktm8efoxryw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

FDA rejects Innocoll's application for postsurgical pain drug

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


FDA rejects Innocoll's application for postsurgical pain drug

Innocoll Holdings PLC received a rejection from the U.S. FDA relating to an application for XARACOLL, the company's product candidate to treat postsurgical pain.

In a preliminary review, the FDA indicated that the application submitted in October was not sufficiently complete to permit a substantive review. It also indicated, among other things, that the drug should be characterized as a drug/device combination, which would require Innocoll to submit additional information.

The company will request a Type A meeting with the FDA to respond to several issues believed to be addressable and seek clarification of what additional information, if any, will be required.